PEOPLE ON THE MOVE
Epizyme
Epigenetics biotech Epizyme has announced Robert Bazemore will succeed Robert Gould as President and CEO from September 10.
Bazemore will join the board of the Massachusetts company after five and a half years as Chief Executive.
“After successfully transitioning the company from an early stage venture backed start-up into a publicly traded development-stage company with a broad research platform, strong balance sheet and experienced leadership team, Robert Gould has worked with the board to identify the right leadership for our next phase of growth,” said David Mott, Epizyme’s lead independent director.
“We are excited to introduce Rob Bazemore as our next CEO and believe that his record of success at Synageva, Johnson & Johnson and Merck ideally position him to lead Epizyme.”